Search Results - "Hutchison, Robert"

Loss of Ezh2 cooperates with Jak2V617F in the development of myelofibrosis in a mouse model of myeloproliferative neoplasm by Yang, Yue, Akada, Hajime, Nath, Dipmoy, Hutchison, Robert E., Mohi, Golam

“…An activating JAK2V617F mutation has been found in ∼50% patients with myelofibrosis (MF). Inactivating mutations in histone methyltransferase enhancer of zeste…”
Get full text

Critical requirement for Stat5 in a mouse model of polycythemia vera by Yan, Dongqing, Hutchison, Robert E., Mohi, Golam

“…The JAK2V617F mutation has been identified in most cases of Ph-negative myeloproliferative neoplasms (MPNs) including polycythemia vera (PV), essential…”
Get full text

Opioid and benzodiazepine utilization patterns in metropolitan and rural Texas by Hutchison, Robert W, Carhart, Joseph

“…Although many drugs are implicated in the crisis, opioids and concomitant sedatives are associated with increased overdose risk in both rural and urban…”
Get more information

Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera–like disease by Akada, Hajime, Yan, Dongqing, Zou, Haiying, Fiering, Steven, Hutchison, Robert E., Mohi, M. Golam

“…A somatic point mutation (V617F) in the JAK2 tyrosine kinase was found in a majority of patients with polycythemia vera (PV), essential thrombocythemia, and…”
Get full text

Cardioprotection and Safety of Dexrazoxane in Patients Treated for Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Advanced-Stage Lymphoblastic Non-Hodgkin Lymphoma: A Report of the Children's Oncology Group Randomized Trial Pediatric Oncology Group 9404 by Asselin, Barbara L, Devidas, Meenakshi, Chen, Lu, Franco, Vivian I, Pullen, Jeanette, Borowitz, Michael J, Hutchison, Robert E, Ravindranath, Yaddanapudi, Armenian, Saro H, Camitta, Bruce M, Lipshultz, Steven E

“…To determine the oncologic efficacy, cardioprotective effectiveness, and safety of dexrazoxane added to chemotherapy that included a cumulative doxorubicin…”
Get full text

Dose-intensive response-based chemotherapy and radiation therapy for children and adolescents with newly diagnosed intermediate-risk hodgkin lymphoma: a report from the Children's Oncology Group Study AHOD0031 by Friedman, Debra L, Chen, Lu, Wolden, Suzanne, Buxton, Allen, McCarten, Kathleen, FitzGerald, Thomas J, Kessel, Sandra, De Alarcon, Pedro A, Chen, Allen R, Kobrinsky, Nathan, Ehrlich, Peter, Hutchison, Robert E, Constine, Louis S, Schwartz, Cindy L

“…The Children's Oncology Group study AHOD0031, a randomized phase III study, was designed to evaluate the role of early chemotherapy response in tailoring…”
Get full text

Critical Role of Jak2 in the Maintenance and Function of Adult Hematopoietic Stem Cells by Akada, Hajime, Akada, Saeko, Hutchison, Robert E., Sakamoto, Kazuhito, Wagner, Kay‐Uwe, Mohi, Golam

“…Jak2, a member of the Janus kinase family of nonreceptor protein tyrosine kinases, is activated in response to a variety of cytokines, and functions in…”
Get full text

STAT3 mutations are not sufficient to induce large granular lymphocytic leukaemia in mice by Dutta, Avik, Yan, Dongqing, Hutchison, Robert E., Mohi, Golam

Get full text

Treating diabetes in underserved populations using an interprofessional care team by W Hutchison, Jr, Robert

“…Abstract Community Health Centers that provide diabetic care for underserved patients have unique challenges. This study describes how interprofessional care…”
Get full text

Genetic ablation of Pim1 or pharmacologic inhibition with TP-3654 ameliorates myelofibrosis in murine models by Dutta, Avik, Nath, Dipmoy, Yang, Yue, Le, Bao T., Rahman, Mohammad Ferdous-Ur, Faughnan, Patrick, Wang, Zhenjia, Stuver, Matthew, He, Rongquan, Tan, Wuwei, Hutchison, Robert E., Foulks, Jason M., Warner, Steven L., Zang, Chongzhi, Mohi, Golam

“…Myelofibrosis (MF) is the deadliest form of myeloproliferative neoplasm (MPN). The JAK inhibitor Ruxolitinib can reduce constitutional symptoms but it does not…”
Get full text

Minimal Treatment of Low-Risk, Pediatric Lymphocyte-Predominant Hodgkin Lymphoma: A Report From the Children's Oncology Group by Appel, Burton E, Chen, Lu, Buxton, Allen B, Hutchison, Robert E, Hodgson, David C, Ehrlich, Peter F, Constine, Louis S, Schwartz, Cindy L

“…Children's Oncology Group study AHOD03P1 was designed to determine whether excellent outcomes can be maintained for patients with low-risk, pediatric…”
Get full text

Hmga2 promotes the development of myelofibrosis in Jak2V617F knockin mice by enhancing TGF-β1 and Cxcl12 pathways by Dutta, Avik, Hutchison, Robert E., Mohi, Golam

“…Myelofibrosis (MF) is a devastating blood disorder. The JAK2V617F mutation has been detected in ∼50% cases of MF. Elevated expression of high-mobility group AT…”
Get full text

A risk-adapted, response-based approach using ABVE-PC for children and adolescents with intermediate- and high-risk Hodgkin lymphoma: the results of P9425 by Schwartz, Cindy L., Constine, Louis S., Villaluna, Doojduen, London, Wendy B., Hutchison, Robert E., Sposto, Richard, Lipshultz, Steven E., Turner, Charles S., deAlarcon, Pedro A., Chauvenet, Allen

“…Current treatment strategies for Hodgkin lymphoma result in excellent survival but often confer significant long-term toxicity. We designed ABVE-PC…”
Get full text

Efficacy of vorinostat in a murine model of polycythemia vera by Akada, Hajime, Akada, Saeko, Gajra, Ajeet, Bair, Alicia, Graziano, Stephen, Hutchison, Robert E., Mohi, Golam

“…The discovery of the JAK2V617F mutation in most patients with Ph-negative myeloproliferative neoplasms has led to the development of JAK2 kinase inhibitors…”
Get full text

Storage, security, and disposal by Hutchison, Robert W

Get more information

Childhood Hodgkin International Prognostic Score (CHIPS) Predicts event‐free survival in Hodgkin Lymphoma: A Report from the Children's Oncology Group by Schwartz, Cindy L., Chen, Lu, McCarten, Kathleen, Wolden, Suzanne, Constine, Louis S., Hutchison, Robert E., Alarcon, Pedro A., Keller, Frank G., Kelly, Kara M., Trippet, Tanya A., Voss, Stephan D., Friedman, Debra L.

“…Background Early response to initial chemotherapy in Hodgkin lymphoma (HL) measured by computed tomography (CT) and/or positron emission tomography (PET) after…”
Get full text

Crizotinib induces apoptosis and gene expression changes in ALK+ anaplastic large cell lymphoma cell lines; brentuximab synergizes and doxorubicin antagonizes by Hudson, Sandra, Wang, Dongliang, Middleton, Frank, Nevaldine, Barbara H., Naous, Rana, Hutchison, Robert E.

“…Background Anaplastic lymphoma kinase (ALK)‐positive anaplastic large cell lymphoma (ALCL) shows 60–70% event free survival with standard treatments. Targeted…”
Get full text

Donor‐derived Philadelphia chromosome‐positive B cell lymphoblastic leukemia presenting with renal allograft involvement in the first year posttransplant by Cassol, Clarissa A., Hod‐Dvorai, Reut, Hubbell, Charlene, Aggarwal, Vikram, Sinha, Shreya, Gentile, Teresa, Hutchison, Robert E.

Get full text

Response-dependent and reduced treatment in lower risk Hodgkin lymphoma in children and adolescents, results of P9426: A report from the Children's Oncology Group by Tebbi, Cameron K., Mendenhall, Nancy P., London, Wendy B., Williams, Jonathan L., Hutchison, Robert E., FitzGerald, Thomas J., de Alarcón, Pedro A., Schwartz, Cindy, Chauvenet, Allen

“…Background Hodgkin lymphoma is highly curable but associated with significant late effects. Reduction of total treatment would be anticipated to reduce late…”
Get full text

Variant histology, IgD and CD30 expression in low‐risk pediatric nodular lymphocyte predominant Hodgkin lymphoma: A report from the Children's Oncology Group by Untanu, Ramona Vesna, Back, Jason, Appel, Burton, Pei, Qinglin, Chen, Lu, Buxton, Allen, Hodgson, David C., Ehrlich, Peter F., Constine, Louis S., Schwartz, Cindy L., Hutchison, Robert E.

“…Background Histologic prognostic factors have been described for nodular lymphocyte predominant Hodgkin lymphoma (NLPHL). This study examines histologic and…”
Get full text